2026-04-14T02:20:35Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/1277052025-11-20T15:54:13Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917
RECERCAT author Martin, Nuria author Guilabert, Patricia author Abarca, Luis author Usua, Gemma author Serracanta, Jordi author Colomina Soler, M. J. (María José) 2019-01-29T12:47:08Z2019-10-23T05:10:13Z2018-10-232019-01-29T12:47:08Z Patients with major burn injury undergo a series of pathophysiologic changes that begin with a systemic inflammatory response and coagulation abnormalities, similar to those experienced by patients with sepsis or severe trauma. Coagulation changes in patients with burns are generally characterized by procoagulant abnormalities, but alterations in fibrinolysis and anticoagulation factors have also been observed. Around 40% of patients with major burn show changes on standard coagulation tests, and these have been related to the severity of the lesions, smoke inhalation, and administration of intensive fluid resuscitation therapy. Current surgical techniques for debridement of burn lesions are aggressive and associated with considerable blood loss. A fast-acting selective enzymatic debriding agent based on bromelain has been recently developed. NexoBrid is indicated for removing eschar in adults with deep partial- and full-thickness thermal burns. A potential effect of oral bromelain on hemostasis has been described, but it is uncertain whether NexoBrid application has a clinically relevant impact in this regard. We present the clinical case of a patient with burns who showed a coagulation abnormality shortly after NexoBrid use. (c) American Burn Association, 2018 info:eu-repo/semantics/openAccess Anticoagulants (Medicina) Fibrinòlisi Hemorràgia Coagulació sanguínia Ferides i lesions Cremades Anticoagulants (Medicine) Fibrinolysis Hemorrhage Blood coagulation Wounds and injuries Burns and scalds Coagulation abnormalities following nexoBrid use: a case report info:eu-repo/semantics/article info:eu-repo/semantics/acceptedVersion